The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Abstract
We assessed the preclinical characteristics of a novel, stringently screened selective estrogen receptor modulator, bazedoxifene acetate, including its ability to bind to and activate estrogen receptors and promote increased bone mineral density and bone strength in rats, and the effects impacting the uterine endometrium, breast cancer cell proliferation, and central nervous system-associated vasomotor responses in an animal model. Bazedoxifene bound to estrogen receptor-alpha with an IC50 of 26 nm, an affinity similar to that of raloxifene. Bazedoxifene did not stimulate proliferation of MCF-7 cells but did inhibit 17beta-estradiol-induced proliferation with an IC50 of 0.19 nm. In an immature rat uterine model, bazedoxifene (0.5 and 5.0 mg/kg) was associated with less increase in uterine wet weight than either ethinyl estradiol (10 microg/kg) or raloxifene (0.5 and 5.0 mg/kg). Histological analysis revealed that coadministration of bazedoxifene also appeared to reduce raloxifene-stimulated endometrial luminal epithelial cell and myometrial cell hypertrophy. In ovariectomized rats, bazedoxifene was associated with significant increases in bone mineral density at 6 wk, compared with control, and better compressive strength of bone samples from the L4 vertebrae, compared with samples from ovariectomized animals. In the morphine-addicted rat model of vasomotor activity, bone-sparing doses of bazedoxifene alone were not associated with 17beta-estradiol inhibition of increased vasomotor activity. Bazedoxifene acetate represents a promising new treatment for osteoporosis, with a potential for less uterine and vasomotor effects than selective estrogen receptor modulators currently used in clinical practice. Controlled clinical trial data will be needed to confirm these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Glass, C. K., Rose, D. W., & Rosenfeld, M. G. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80066-x · Cited by 698
Basic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., & Bensch, W. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116985 · Cited by 609
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
McDonnell, D. P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.6.659 · Cited by 526
Harris, H. A., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2002) · Endocrinology · doi:10.1210/en.2002-220403 · Cited by 357
Self-citationStearns, V., Ullmer, L., Lopez, J. F., Smith, Y., Isaacs, C., & Hayes, D. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11774-0 · Cited by 354
Role of Hormones in Mammary Cancer Initiation and Progression
Russo, I. H., & Russo, J. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018770218022 · Cited by 337
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296
Tamoxifen treatment and gynecologic side effects: a review
MOURITS, M. (2001) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(00)01196-0 · Cited by 200
Chlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G., Burstein, H. J., Eisen, A., Lipkus, I., & Pfister, D. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.029 · Cited by 197
Adverse events reported by postmenopausal women in controlled trials with raloxifene
Davies, G. (1999) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00476-1 · Cited by 195
Pharmacokinetic and Pharmacologic Variation Between Different Estrogen Products
O'Connell, M. B. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04143.x · Cited by 184
Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2002) · Science · doi:10.1126/science.1070442 · Cited by 179
Estrogen Regulation of Tissue-specific Expression of Complement C3
Sundstrom, S. A., Komm, B. S., Ponce-de-Leon, H., Yi, Z., Teuscher, C., & Lyttle, C. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84798-1 · Cited by 178
Self-citationLonard, D. M., & Smith, C. S. (2002) · Steroids · doi:10.1016/s0039-128x(01)00133-7 · Cited by 170
Ke, H. Z., Paralkar, V. M., GRASSER, W. A., Crawford, D. T., Qi, H., Simmons, H. A., Pirie, C. M., Chidsey-Frink, K. L., Owen, T. A., Smock, S. L., et al. (1998) · Endocrinology · doi:10.1210/endo.139.4.5902 · Cited by 161
Mammary Gland Development Is Mediated by Both Stromal and Epithelial Progesterone Receptors
Humphreys, R. C., Lydon, J. P., O’Malley, B. W., & Rosen, J. M. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.9891 · Cited by 154
The ligand binding profiles of estrogen receptors α and β are species dependent
Harris, H. A., Bapat, A. R., Gonder, D. S., & Frail, D. E. (2002) · Steroids · doi:10.1016/s0039-128x(01)00194-5 · Cited by 150
Self-citationDesign, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens
Miller, C. P., Collini, M. D., Tran, B. D., Harris, H. A., Kharode, Y. P., Marzolf, J. T., Moran, R. A., Henderson, R. A., Bender, R. H. W., Unwalla, R. J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010086m · Cited by 150
Self-citationThe Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor- B in HepG2 Cells
Harnish, D. C., Scicchitano, M. S., Adelman, S. J., Lyttle, C. R., & Karathanasis, S. K. (2000) · Endocrinology · doi:10.1210/endo.141.9.7646 · Cited by 148
Self-citationEffects of raloxifene hydrochloride on the endometrium of postmenopausal women
Boss, S. M., Huster, W. J., Neild, J. A., Glant, M. D., Eisenhut, C. C., & Draper, M. W. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70091-7 · Cited by 144
Clinical potential of new antiestrogens.
Gradishar, W., & Jordan, V. C. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.840 · Cited by 120
Goldstein, S. R., & Nanavati, N. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.123938 · Cited by 120
Komm, B. S., & Lyttle, C. R. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04039.x · Cited by 101
Self-citationActivity of Raloxifene in Immature and Ovariectomized Rat Uterotrophic Assays
Ashby, J., Odum, J., & Foster, J. R. (1997) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1997.1108 · Cited by 93
Ma, Y. L., Bryant, H. U., Zeng, Q., Schmidt, A., Hoover, J. L., Cole, H. W., Yao, W., Jee, W. S. S., & Sato, M. (2003) · Endocrinology · doi:10.1210/en.2002-221061 · Cited by 91
Raloxifene: A selective estrogen receptor modulator
Sato, M., Glasebrook, A. L., & Bryant, H. U. (1994) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf02383389 · Cited by 76
The effect of estrogens and antiestrogens in a rat model for hot flush
Merchenthaler, I. J., Funkhouser, J. M., Carver, J. M., Lundeen, S. G., Ghosh, K., & Winneker, R. C. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00045-0 · Cited by 75
van den Bemd, G.-J. C. M., Kuiper, G. G. J. M., Pols, H. A. P., & van Leeuwen, J. P. T. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0864 · Cited by 75
Tamoxifen to raloxifene and beyond
O'Regan, R. M., & Jordan, V. C. (2001) · Seminars in Oncology · doi:10.1053/sonc.2001.23492 · Cited by 48
Hadzopoulou‐Cladaras, M., & Cardot, P. (1993) · Biochemistry · doi:10.1021/bi00088a018 · Cited by 34
Regulation of Bone Cell Function by Estrogens
Komm, B. S., & Bodine, P. V. N. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50011-8 · Cited by 17
Self-citation
Cited by
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Metadata
- Authors
- Komm, B. S., Kharode, Y. P., Bodine, P. V. N., Harris, H. A., Miller, C. P., & Lyttle, C. R.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-09-01
- Volume
- 146
- Issue
- 9
- Pages
- 3999-4008
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2026579016
- Cited by
- 298
- References
- 37
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.